Browse
Submit Data
Databases
API
Help

Dataset Information

20 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Safety and efficacy of postoperative adjuvant chemotherapy with L-OHP base regimen followed by UFT plus LV for resectable liver metastases from colorectal cancer

ABSTRACT: Interventions: Postoperative adjuvant chemotherapy with L-OHP base regimen (6courses of mFOLFOX6 or 4courses of CapeOX) followed by 3courses of UFT plus LV. Primary outcome(s): the completion rate Study Design: Single arm Non-randomized

DISEASE(S): Resectable Liver Metastases From Colorectal Cancer

PROVIDER: 2635906 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

LOFT trial

Project description:Interventions: Postoperative adjuvant chemotherapy with L-OHP base regimen (6courses of mFOLFOX6 or 4courses of CapeOX) followed by 3courses of UFT plus LV.;CRLM, FOLFOX Primary outcome(s): the completion rate Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

| 2612975 | ecrin-mdr-crc

Ribo-seq of human colorectal cancer cell line HCT116/L-OHP against HCT116

Project description:Oxaliplatin (L-OHP) serves as a standard chemotherapy for colorectal cancer, while the drug resistance is still a considerable challenge. Dysregulation of lncRNA is involved in cancer and recent translatomics has found some alleged lncRNA actually contained small open reading frames and could encode short peptides. This ribosome footprint profiling (Ribo-seq) was a paired-end sequencing and aimed to investigate whether lncRNA could regulate oxaliplatin resistance in colorectal cancer by encoding short peptides.

2021-11-12 | E-MTAB-10805 | biostudies-arrayexpress

RNA-seq of human colorectal cancer cell line HCT116/L-OHP against HCT116

Project description:Oxaliplatin (L-OHP) serves as a standard chemotherapy for colorectal cancer, while the drug resistance is still a considerable challenge. A number of previously unknown transcripts have been identified in recent years, the vast majority of which are considered long non-coding RNA (lncRNA). Dysregulation of the lncRNA is involved in the genesis and progression of cancer. This RNA-seq was a paired-end sequencing and aimed to investigate the expression profile of lncRNA associated with oxaliplatin resistance in colorectal cancer.

2021-11-12 | E-MTAB-10806 | biostudies-arrayexpress

Uracil and Tegafur/Leucovorin (UFT/LV) Versus UFT/LV+ Polysaccharide-K (PSK) for Stage IIIa/IIIb Colorectal Cancer

Project description:The purpose of this study is to conduct a randomised controlled trial (RCT) comparing UFT/LV and UFT/LV + PSK in patients with histological stage IIIa/IIIb colorectal cancer who have undergone curative surgery without residual cancer using 3-year disease free survival (DFS) as the primary endpoint, and also to analyze the 3-year overall survival (OS), compliance, adverse events, quality of life (QOL) and relationship with tumor factors.

| 2041766 | ecrin-mdr-crc

A Randomized Trial of Adjuvant Chemotherapy with UFT / LV versus PSK / UFT / LV following curative resection for Stage II / III Colorectal Cancer

Project description:Interventions: Group A (standard therapy group:UFT/LV 6M): Administration of 5 courses (6 months) of a schedule in which one course consists of UFT (300 mg/m2/day) and LV (75 mg/day) for 28 consecutive days followed by 7 days off the drugs. Group B (trial therapy group: PSK/UFT/LV 6M): Administration of 5 courses (6 months) of a schedule in which one course consists of UFT (300 mg/m2/day) and LV (75 mg/day) for 28 consecutive days followed by 7 days off the drugs. And administration of every day PSK (3g/body) for 6 months. Group C (trial therapy group: PSK/UFT/LV 12M): Administration of 10 courses (12 months) of a schedule in which one course consists of UFT (300 mg/m2/day) and LV (75 mg/day) for 28 consecutive days followed by 7 days off the drugs. And administration of every day PSK (3g/body) for 12 months. Primary outcome(s): 3 year desease free survival rate Study Design: Parallel Randomized

| 2620921 | ecrin-mdr-crc

A Phase III Trial Comparing UFT+PSK to UFT+LV in Stage IIB, III Colorectal Cancer

Project description:To compare the efficacy of tegafur/uracil (UFT) plus folinate calcium (leucovorin: LV) administered orally and UFT plus Krestin (PSK) administered orally enrolling patients with pTNM stage IIB or III colorectal cancer as subjects in a multicenter collaborative randomized open-label comparative controlled study and consequently to determine the usefulness of the above regimens as adjuvant therapy after surgery.

| 2033414 | ecrin-mdr-crc

BASE

Project description:BASE – Biomes of Australian Soil Environments

| PRJEB7626 | ENA

Randomized phase II study with UFT capsule /LV or UFT E-granule /LV adjuvant chemotherapy for patients with completely resected high-risk stage II and III colorectal cancer

Project description:Interventions: UFT capsule / LV for 28 days with 7 days rest for 180days (6months)(1 course=5weeks, 35days). UFT E-granule / LV for 28 days with 7 days rest for 180days (6months)(1 course=5weeks, 35days). Primary outcome(s): treatment complete rate Study Design: Parallel Randomized

| 2626356 | ecrin-mdr-crc

Switch maintenance using UFT/LV therapy after Oxaliplatin based adjuvant chemotherapy for StageIV colorectal cancer

Project description:Interventions: Within 8 weeks after Oxaliplatin based chemotherapy (UFT/LV Switch maintenance:5 course) UFT/LV p.o:4weeks on 1week off to be repeated every 5weeks Primary outcome(s): The complete of treatment,Safety Study Design: Single arm Non-randomized

| 2624724 | ecrin-mdr-crc

Switch maintenance using UFT/LV therapy after Oxaliplatin based adjuvant chemotherapy for StageIII colorectal cancer

Project description:Interventions: Within 8 weeks after Oxaliplatin based chemotherapy (UFT/LV switch maintenance:5 course) UFT/LV p.o(4 weeks on,1week off ) to be repeated every 5 weeks. Primary outcome(s): The complete rate of treatment, Safety Study Design: Single arm Non-randomized

| 2624723 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data